Aegerion Pharmaceuticals said today that the FDA had approved lomitapide (Juxtapid) to help further lower cholesterol in patients with homozygous familial hypercholesterolemia. The approval comes with ...

Discover comprehensive details about Lomitapide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Are you taking Lomitapide? Are you aware of the dangers of combining Lomitapide with certain foods, herbs, or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable side ...

Please provide your email address to receive an email when new articles are posted on . Patients with adult homozygous familial hypercholesterolemia responded favorably to lomitapide when administered ...

Homozygous familial hypercholesterolemia is a rare genetic condition that is often characterized by an increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide decreases ...

A total of 46 pediatric patients were enrolled, with 43 patients completing the run-in phase and entering the efficacy phase. 20 patients were between 5 and 10 years of age. 23 patients were between ...

The FDA has approved lomitapide (Aegerion Pharmaceuticals, Cambridge, MA) as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce LDL-C, total ...

FDA reviewers have raised no new concerns about lomitapide ahead of a Wednesday meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. The FDA today released briefing documents that ...

Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous familial hypercholesterolaemia in whom diet and other drugs do not sufficiently ...

London, UK - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the lomitapide preparation Lojuxta (Aegerion Pharmaceuticals) be ...

Aegerion anticipates reimbursement decisions in some countries beginning in 2014. Aegerion has launched Lojuxta in the UK and Germany; however, limited uptake is expected until reimbursement decisions ...